SUPN falls 22% as deal mechanics dominate the register

Supernus Pharmaceuticals has collapsed 22% in a single session, leaving the stock down 19% on the week and 21% over the past month, the kind of move that reorders every positioning story in the register.

The price action is the story. The October 29 earnings release for the Indivior acquisition deal produced a 1.7% one-day move, but the real shock came on November 3, when the stock dropped from the mid-$30s to close at $28.15. The previous ORTEX note on this ticker, published October 28, described short sellers retreating and a broadly relaxed lending market. That picture has now changed sharply. Short interest has risen 10% over the past week to 8.1% of the free float, reversing the covering trend that defined October. The short score ticked up to 52.9 from a low of 48.5 on October 27, though it remains in a neutral range rather than signalling an extreme bearish position. Borrow conditions are still loose: availability is running at 563%, meaning roughly five-and-a-half shares are available to lend for every one currently borrowed. Cost to borrow has edged up 13% on the week but remains negligible at 0.51%. The lending market is not telling a squeeze story; it is telling a story of fresh shorts being added into a falling stock with ample capacity to do so.

Options positioning offers almost no incremental signal. The put/call ratio has drifted slightly lower to 0.992, just below its 20-day average of 0.995 and barely a quarter of a standard deviation from the mean. The 52-week range on the PCR runs from 0.004 to 1.017, so the current reading sits near the top of the historical range in absolute terms, but the negligible z-score means options traders as a whole have not dramatically repositioned in response to this week's drop.

The Street was broadly constructive before the fall. Barclays raised its target to $45 from $43 on October 28 while maintaining an Overweight rating, one day before the stock began its slide. The consensus mean target is $49.50, implying roughly 76% upside to the November 3 close at $28.15. That gap is striking but reflects targets set before this week's move rather than a new bull thesis. Valuation multiples have compressed sharply with the price: the EV/EBITDA multiple has dropped by 1.24 turns over the week, and the P/E has fallen nearly one turn. The earnings yield factor now ranks in the 95th percentile, while the EV/EBIT factor scores in the 77th, both reflecting how cheap the stock looks on trailing numbers relative to peers after the selloff. EPS momentum over 30 days ranks just 16th percentile, however, flagging that forward estimate revisions have been running against the stock.

The index mechanics are worth noting. ORTEX puts the probability of a share-count increase in the CRSP US Small index at 81%, tied to the Indivior acquisition deal becoming effective. The equivalent forecast for the S&P TMI and S&P Completion indices is 80%, and for the MSCI World Small index it is 99%. These are forecasts linked to the off-cycle deal, with announcement dates estimated around November 5 to 6 and an effective date of November 9. The implied buying flow for the CRSP rebalance alone is $72 million, roughly 1.1 days of average volume. These are mechanical flows driven by index rules, not expressions of investment conviction, but they are real demand that arrives on a defined schedule.

The activist register adds further texture. Two Seas Capital filed a Schedule 13D amendment in December 2025 and last disclosed a stake just below the 5% threshold at 4.98%, down from 5.7%. Oaktree Capital, also a 13D filer, has dramatically reduced its reported stake from 5.69% to 0.76% as of its August 2026 amendment. As always with 13D/G filings, these stakes are as-last-disclosed and positions can move substantially without a further filing once below 5%.

What to watch next is the interplay between the index mechanics due around November 6 to 9, further analyst target revisions now that the stock trades well below every published price objective, and whether fresh short interest continues to build or whether the discount to consensus targets attracts long buyers before the next earnings event in late February 2027.